Registration and prospectus / Salarius Pharmaceuticals, Inc. | Tables in SEC filings

SLRX Salarius Pharmaceuticals, Inc.

IPO registration

The pro forma combined basic and diluted earnings per share have been adjusted to reflect the pro forma net income (loss) for the nine months ended September 30, 2024, and the year ended December 31, 2023. In addition, the number of shares used to calculate the pro forma combined basic and diluted net income (loss) per share has been adjusted to reflect the estimated total number of shares of common stock of the combined company that would be outstanding at the Merger Closing, including the shares to be issued in the Qualified Financing, as if they have been outstanding for the entirety of the periods presented. For the nine months ended September 30, 2024, and the year ended December 31, 2023, the pro forma weighted average shares outstanding has been calculated as follows:

September 30, 2024	December 31, 2023
Weighted-average Decoy common shares outstanding – basic and diluted			1,287,930		1,287,930	Decoy convertible notes equivalent shares	1,816,945		1,816,945	Total	3,104,875		3,104,875	Application of exchange ratio	2.2853		2.2853	Adjusted Weighted-average Decoy common shares equivalents outstanding – basic and diluted	7,095,571		7,095,571	$6.0 million of Qualified Financing	3,333,333		3,333,333	$0.5 million of SPA Financing	142,410		142,410	Weighted-average Salarius common shares outstanding	801,395		408,078	Conversion of Salarius RSUs to Salarius common shares	131		131	Pro forma combined weighted average number of shares of common stock – basic and diluted	11,372,840		10,979,523

SP-2577	SP-3164
Research and development costs by candidates and by categories:		Nine months ended September 30,
		2024	2023			2024			2023
Outsourced research and development costs		$	258,417	$	1,432,648	$	56,609	$	2,647,128	Employee-related costs	—	1,539,865	—	207,569	Manufacturing and laboratory costs	75,205	118,150	204,452	1,168,434	Total research and development costs	$	333,622	$	3,090,663	$	261,061	$	4,023,131

Name and Principal Position	Year			Salary			Stock Awards (2)			Option Awards (3)			All Other Compensation			Total
David J. Arthur President and Chief Executive Officer			2024			$			176,153	(1)	—			$	8,265	$	550,032	(4)	$			734,450	2023	$			500,000	$	31,400	—	$	13,200	(5)	$			544,600	Mark J. Rosenblum Executive Vice President, Finance and Chief Financial Officer	2024			$			330,000	—	$	11,372	$	9,050	(5)	$			350,422	2023	$			330,000	$	12,560	—	$	13,200	(5)	$			355,760

Name	Number of Shares Subject to Outstanding Stock Options			Number of Restricted Shares of Common Stock
Tess Burleson			2,908			180	Arnold C. Hanish	2,908			180	Paul Lammers	2,908			180	Jonathan Lieber	2,878			180	Bruce J. McCreedy	2,908			180	William K. McVicar	2,908			180

Name and Address	Beneficial Ownership		Percent of Class(1)
Stockholders of 5% or more(2)		—		—	Officers and Directors	Frederick E. Pierce(3)	760,495	6.4	%
Barbara Hibner(4)		760,495		6.4	%
Peter Marschel(5)		760,495		6.4	%
Mark J. Rosenblum(6)		5,098		*
Tess Burleson(7)		3,269		*
Arnold C. Hanish(8)		3,341		*
Jonathan Lieber(9)		3,246		*
Paul Lammers(10)		3,123		*
Bruce J. McCreedy(11)		3,131		*
William K McVicar(12)		3,308		*
David J. Arthur(13)		11,601		*
All Directors and Officers as a group(14)		2,317,602		19.4	%

Table search / Registration and prospectus / Salarius Pharmaceuticals, Inc.

80 results

Top filers

Top filing types

Recent filing years